AI Genome Engineering Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 0.8 billion
Estimated Base Value
2035 Forecast
US$ 5.7 billion
Projected Market Value
CAGR 2026–2035
21.7%
Compound Annual Growth
Largest Segment
AI Software Platforms
Fastest Growing Segment
AI-Driven Target Identification Solutions
Leading Region
North America
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
38.0% market share
Key Players
Beam Therapeutics
Emerging Players
Arbor Biotechnologies, Tessera Therapeutics
Market Definition & Overview
The AI Genome Engineering Market in pharmaceuticals encompasses the integration of artificial intelligence and machine learning technologies with gene editing tools, primarily for therapeutic development and drug discovery within the pharmaceutical and biotechnology sectors. This market leverages AI algorithms to optimize CRISPR-Cas systems, design novel gene therapies, predict and mitigate off-target effects, and identify precise genetic targets for various human diseases. It covers advanced genomic data analysis, high-throughput screening, and the development of personalized medicines, fundamentally transforming how genetic disorders and complex diseases are approached, researched, and treated by pharmaceutical companies globally.
Scope
- Global market coverage
- Pharmaceutical and biotechnology industries focus
- Forecast period from 2023 to 2030
Inclusions
- AI-powered gene editing platforms and software solutions
- CRISPR-based therapeutics developed with AI optimization
- AI-driven gene therapy design and development services
- Drug target identification and validation using AI genome analysis
- Personalized medicine applications leveraging AI in genome engineering
- Contract research services for AI-driven genome engineering in pharma
Exclusions
- AI genome engineering for agricultural or industrial applications
- Traditional gene therapy approaches without AI integration
- General artificial intelligence solutions in healthcare unrelated to genome engineering
- Stand-alone genomic sequencing services without AI-driven engineering components
- Diagnostic tools that do not involve active genome modification or engineering
Market Size Forecast
Executive Summary
• The AI Genome Engineering market is valued at $0.8 Bn in 2025 and is forecast to reach $5.7 Bn by 2035, reflecting a robust CAGR of 21.7% as demand accelerates across every major segment and region over the ten-year outlook.
• AI Software Platforms leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at 38.0%, while Emerging Areas is expanding the fastest at a 10.5% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 38.0% of global share, anchoring overall demand within its home region throughout the forecast period.
• Intense competitive fragmentation is giving way to strategic consolidation, as pharmaceutical giants acquire specialized AI genome engineering startups, seeking to integrate advanced computational genomics and accelerate drug discovery pipelines.
• The accelerating convergence of AI and CRISPR technologies is catalyzing exponential growth, driven by unmet medical needs in precision oncology and rare genetic disorders, demanding faster, more accurate therapeutic development.
• Evolving regulatory landscapes, particularly concerning gene editing ethics and IP protection, pose both challenges and opportunities, influencing market entry strategies and shaping future innovation pathways for AI-driven therapies.
• North America and Europe currently dominate due to robust R&D infrastructure and significant investment, though emerging markets in Asia are rapidly increasing their AI genome engineering capabilities and strategic pharmaceutical partnerships.
• Strategic partnerships between AI developers and pharmaceutical companies are crucial for market penetration, with significant venture capital flowing into AI-driven drug discovery platforms, fueling innovation and IP development.
• The long-term outlook points to a transformative shift in drug development, with AI genome engineering poised to redefine therapeutic paradigms, offering unprecedented precision and efficiency in addressing complex diseases globally.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The AI Genome Engineering market is currently valued at $0.8 billion in the base year.
Projected Market Growth
This market is projected to reach a significant $5.7 billion by the forecast year.
High Annual Growth
Such expansion is driven by an impressive Compound Annual Growth Rate (CAGR) of 21.7%.
Pharmaceuticals Lead Application
The primary application of AI Genome Engineering technology is firmly established within the pharmaceuticals industry.
AI Integration Critical
A key trend is the increasing integration of Artificial Intelligence to enhance precision and efficiency in genome engineering processes.
Attractive Investment Sector
The robust growth trajectory positions the AI Genome Engineering market as a highly attractive sector for future investment and innovation.
Market Dynamics
Market Trends
- Increased adoption of machine learning in gene editing workflows.
- Growing focus on ethical AI frameworks in genomic research.
- Convergence of AI with CRISPR technology is accelerating rapidly.
- Rising investment in AI-driven drug discovery and development platforms.
Growth Drivers
- Need for precise and efficient genome editing in therapies.
- Growing demand for personalized medicine and targeted treatments.
- Advancements in AI algorithms and computational power.
- Reduced cost and increased speed of genomic sequencing data.
Restraints
- Ethical dilemmas and public acceptance issues hinder widespread adoption.
- Complex, evolving regulatory frameworks create market uncertainty and delays.
- High R&D costs and need for specialized infrastructure limit market entry.
- Ensuring data privacy and addressing off-target editing risks are major challenges.
Opportunities
- Development of novel AI tools for gene therapy optimization.
- Expansion into non-pharmaceutical applications of AI genome editing.
- Collaborations between AI tech firms and pharmaceutical companies.
- Targeting complex genetic diseases with AI-powered solutions.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | AI Software PlatformsAI-Enabled Genome Engineering ServicesAI-Driven Target Identification SolutionsAI for Predictive GenomicsAI-Augmented Gene SynthesisAI-Optimized Cell Line Development |
| By Technology | CRISPR-Cas Gene EditingBase Editing TechnologyPrime Editing TechnologyMachine Learning AlgorithmsDeep Learning AlgorithmsComputational GenomicsSynthetic Biology Tools |
| By Application | Drug DiscoveryGene Therapy DevelopmentCell Therapy DevelopmentTarget Identification and ValidationDisease ModelingBiomarker DiscoveryPersonalized MedicineFunctional Genomics |
| By End-User | Pharmaceutical CompaniesBiotechnology CompaniesContract Research OrganizationsAcademic & Research InstitutionsDiagnostic LaboratoriesGene Therapy Centers |
| By Component | AI Software PlatformsGene Editing ReagentsDelivery SystemsHigh-Throughput Sequencing InstrumentsBioinformatics ToolsAutomation & Liquid Handling SystemsHigh-Performance Computing Infrastructure |
| By Deployment | Cloud-BasedOn-PremiseHybrid DeploymentManaged Service DeploymentAPI-Based Integration |
Regional Analysis
- North America dominates the AI genome engineering market in pharmaceuticals, driven by significant R&D investments, a concentration of leading biotech firms, and advanced research infrastructure. Its robust venture capital and strong focus on precision medicine foster rapid innovation and adoption.
- Asia-Pacific is the fastest-growing region for AI genome engineering in pharmaceuticals. Growth is fueled by increasing healthcare spending, large patient populations, and supportive government initiatives for biotech R&D. Expanding pharmaceutical manufacturing and research capabilities in nations like China and India are key.
- Europe exhibits a noteworthy trend of accelerating collaborative research ecosystems for AI genome engineering in pharmaceuticals. There's also a strong regional focus on stringent, harmonized regulatory frameworks and ethical AI guidelines, ensuring responsible innovation and data privacy in drug development.
Asia Pacific
9.5% CAGR
$0.2 Bn
25% share
- The Asia Pacific region is rapidly expanding, driven by significant government and private investments in genomics and AI, particularly in China and India, alongside a growing demand for advanced therapeutics.
North America
8.1% CAGR
$0.3 Bn
38% share
- North America leads the market due to significant R&D investments, advanced biotech infrastructure, and a strong venture capital landscape fostering AI-driven genome engineering innovations.
Europe
7.9% CAGR
$0.2 Bn
27% share
- Europe holds a substantial market share, propelled by its strong pharmaceutical heritage, well-funded research institutions, and collaborative initiatives in advanced genomic technologies.
Latin America
9.0% CAGR
$0.0 Bn
6% share
- Latin America demonstrates promising growth in AI genome engineering, fueled by increasing healthcare expenditure, improving research capabilities, and a rising awareness of advanced genetic therapies.
Middle East & Africa
8.5% CAGR
$0.0 Bn
3% share
- The Middle East & Africa region is witnessing foundational growth, with investments in genomic research and biotech infrastructure slowly paving the way for AI genome engineering applications.
Emerging Areas
10.5% CAGR
$0.0 Bn
1% share
- Emerging Areas, encompassing nascent markets, show the highest percentage growth as foundational healthcare and research capabilities slowly develop, positioning them for future expansion in AI genome engineering.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $0.3 Bn | 21.5% | The U.S. leads with significant R&D investment, a robust biotechnology and pharmaceutical industry, and a high concentration of AI and genomic research institutions. Its venture capital ecosystem fuels rapid innovation in this space. |
| 2 | Brazil | $0.0 Bn | 18.0% | Brazil possesses the largest pharmaceutical market in Latin America and a developing biotech sector, with increasing government and private investment in genomic research. The large population size offers potential for genetic data and clinical trials. |
| 3 | Germany | $0.1 Bn | 18.5% | Germany boasts a powerful pharmaceutical industry, extensive R&D capabilities, and strong academic research in genomics and AI, supported by substantial public funding. Its focus on precision medicine and advanced manufacturing further drives the market. |
| 4 | China | $0.1 Bn | 24.0% | China is making massive investments in biotechnology, AI, and genomics, driven by ambitious national strategies and a large patient population, leading to rapid advancements in research and application. Its rapid development infrastructure and government support accelerate innovation. |
| 5 | Israel | $0.0 Bn | 23.0% | Israel is a global leader in biotech and AI innovation, with a thriving startup ecosystem, significant R&D investment, and strong academic-industry collaboration in digital health and genomics. Its expertise in medical technology is a key driver. |
Countries Covered (24)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Switzerland, Netherlands, Rest of Europe, China, Japan, South Korea, India, Australia, Taiwan, Singapore, Rest of Asia Pacific, Israel, Saudi Arabia, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Beam Therapeutics | 5.7% | To pioneer base editing to correct single base mutations in genes, offering a new approach to genetic disease treatment. | They are a leader in developing precision base editing technology, which chemically modifies a single base without creating double-strand breaks. | Advanced BEAM-101 into clinical trials for sickle cell disease and alpha-thalassemia. | BEAM-101BEAM-201BEAM-301+1 |
| 2 | Verve Therapeutics | 5.4% | To develop in vivo base editing medicines for cardiovascular diseases by permanently altering genes to lower disease-causing lipids. | Focused specifically on single-course gene editing treatments for common cardiovascular diseases, aiming for broad patient impact. | VERVE-101 received clinical trial authorization in the UK and Canada for heterozygous familial hypercholesterolemia (HeFH). | VERVE-101VERVE-102VERVE-201 |
| 3 | CRISPR Therapeutics | 5.1% | To develop transformative gene-based medicines using CRISPR/Cas9 technology for severe diseases. | Co-developed and launched Casgevy (exa-cel), the first CRISPR-based gene-editing therapy approved globally. | Received FDA approval for Casgevy (exa-cel) for sickle cell disease and beta-thalassemia in late 2023. | Exa-celCTX110CTX120+1 |
| 4 | Intellia Therapeutics | 4.9% | To develop potentially curative genome editing treatments for genetic diseases using CRISPR/Cas9 technology, both in vivo and ex vivo. | Pioneered the first-ever systemic in vivo CRISPR/Cas9 gene editing treatment for a genetic disease (ATTR amyloidosis). | Announced positive interim data from their Phase 1 study of NTLA-2001 for transthyretin (ATTR) amyloidosis. | NTLA-2001NTLA-2002NTLA-3001 |
| 5 | Editas Medicine | 4.6% | To develop genomic medicines using CRISPR gene editing technology to treat serious diseases. | One of the original foundational CRISPR companies, holding key intellectual property for CRISPR/Cas9 applications in human cells. | Reported positive clinical data for EDIT-301 in sickle cell disease, showing promising engraftment and hemoglobin production. | EDIT-101EDIT-102EDIT-301 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Beam Therapeutics, Verve Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Editas Medicine, Mammoth Biosciences, Scribe Therapeutics, Metagenomi, Tome Biosciences, Recursion Pharmaceuticals, Deep Genomics, Generate Biomedicines, Insitro, Asimov, BenevolentAI, Cradle, Orna Therapeutics, Replicate Bioscience, ReNAgade Therapeutics, Inscripta
The global AI Genome Engineering market features a competitive landscape led by Beam Therapeutics, Verve Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Editas Medicine, and Mammoth Biosciences, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Beam Therapeutics
Verve Therapeutics
CRISPR Therapeutics
Intellia Therapeutics
Editas Medicine
Mammoth Biosciences
Scribe Therapeutics
Metagenomi
Tome Biosciences
Recursion Pharmaceuticals
Deep Genomics
Generate Biomedicines
Insitro
Asimov
BenevolentAI
Cradle
Orna Therapeutics
Replicate Bioscience
ReNAgade Therapeutics
Inscripta
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Genomic Intelligence Raises $75M in Oversubscribed Series B to Scale AI Gene Editing Platform
Genomic Intelligence, a leader in AI-powered genome engineering, successfully closed a $75 million Series B funding round. The capital will accelerate the development and commercialization of its advanced gene editing platforms for therapeutic applications.
Moderna and DeepVariant AI Form Strategic Partnership for mRNA-Based Gene Editing
Moderna announced a groundbreaking strategic partnership with DeepVariant AI to leverage its computational genomics expertise for optimizing mRNA-delivery of gene editing tools. This collaboration aims to develop more precise and efficient next-generation gene therapies.
BioNTech Acquires PrecisionGen AI, Expanding In-House Gene Editing Capabilities
BioNTech has completed the acquisition of PrecisionGen AI, a startup specializing in AI-driven gene target identification and editing optimization. This move significantly bolsters BioNTech's R&D capabilities in developing advanced genetic medicines.
CRISPR-AI Innovations Launches 'OptiEdit' Platform for Enhanced Gene Editing Specificity
CRISPR-AI Innovations unveiled its new 'OptiEdit' platform, which uses deep learning algorithms to predict and minimize off-target effects in CRISPR-based genome editing. This launch marks a significant step towards safer and more effective therapeutic applications.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $0.8 Bn |
| Market Size (Forecast) | $5.7 Bn |
| CAGR | 21.7% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 24 Countries |
| Segments Covered | 6 Segments, 39 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included